Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $79
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has maintained an Outperform rating on LeMaitre Vascular (NASDAQ:LMAT) and increased the price target from $69 to $79.
May 03, 2024 | 8:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LeMaitre Vascular's Outperform rating is maintained by Barrington Research, with a raised price target from $69 to $79.
The increase in price target by Barrington Research suggests a positive outlook on LeMaitre Vascular's future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100